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What is the key question? 34 
Is Physiotherapy, speech and language therapy intervention (PSALTI) effective for patients 35 
with refractory chronic cough? 36 
 37 
What is the bottom line? 38 
PSALTI significantly reduced objective cough frequency and significantly improved quality 39 
of life when compared to control intervention. 40 
 41 
Why read on? 42 
This study is the first multi-centred randomised controlled trial that demonstrates 43 
improvements with Physiotherapy and Speech and Language Therapy Intervention (PSALTI) 44 
compared to control intervention using objective outcome measures.  45 
 46 
Twitter Feed (140 characters including spaces): Physiotherapy, speech and language therapy 47 
(PSALTI) reduces cough and improves quality of life in refractory chronic cough patients 48 
 49 
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ABSTRACT  75 
Background Physiotherapy and Speech and Language Therapy are emerging non-76 
pharmacological treatments for refractory chronic cough. We aimed to investigate the efficacy 77 
of a Physiotherapy, Speech and Language Therapy Intervention (PSALTI) to improve health 78 
related quality of life (HRQoL) and to reduce cough frequency in patients with refractory 79 
chronic cough. 80 
Methods In this multi-centre randomised controlled trial, patients with refractory chronic 81 
cough were randomised to four weekly 1:1 sessions of either: PSALTI consisting of education, 82 
laryngeal hygiene and hydration, cough suppression techniques, breathing exercises and 83 
psycho-educational counselling or control intervention consisting of healthy lifestyle advice. 84 
We assessed the change in health related quality of life at week 4 with the Leicester Cough 85 
Questionnaire (LCQ). Secondary efficacy outcomes included 24-hour objective cough 86 
frequency (Leicester Cough Monitor) and cough reflex sensitivity. The primary analysis used 87 
an analysis of covariance adjusted for baseline measurements with the intention-to-treat 88 
population. This study was registered at UK Clinical Research Network (UKCRN ID 10678) 89 
Findings Between December 2011, and April 2014, we randomly assigned 75 patients who 90 
underwent baseline assessment (34 PSALTI and 41 control). In the observed case analysis, 91 
HRQoL (LCQ) improved on average by 1.5 (95%CI: 0.21 to 2.85) points more in PSALTI 92 
group than with control (p=0.024). Cough frequency improved by 41% (95%CI: 36% to 95%) 93 
in PSALTI group relative to control (p=0.030). The improvements within the PSALTI group 94 
were sustained up to three months. There was no significant difference between groups in the 95 
concentration of capsaicin causing 5 or more coughs.  96 
Interpretation Greater improvements in HRQoL and cough frequency were observed with 97 
PSALTI intervention.  Our findings support the use of PSALTI for patients with refractory 98 
chronic cough. 99 
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INTRODUCTION 103 
Chronic cough, defined as a cough lasting more than eight weeks, [1] is a prevalent disorder in 104 
both the community, [2] and secondary care sectors, accounting for up to 20% of respiratory 105 
out-patient clinic referrals. [1, 3] The most common causes of cough in a non-smoking patient 106 
with a normal chest radiograph and spirometry are asthma, gastro-oesophageal reflux disease, 107 
and rhinitis (upper airway cough syndrome). [1, 4, 5] For a significant number of patients, the 108 
cough may remain unexplained or refractory to treatment despite extensive investigation and 109 
therapeutic trials. [6] Cough is associated with significant physical and psychological morbidity 110 
as well as impaired quality of life. [7-9] There are few effective antitussive therapies for 111 
refractory chronic cough. [10, 11] Recent studies suggest a potential role for gabapentin, 112 
pregabalin, amitriptyline, morphine and P2X3 receptor inhibitors but they are all associated 113 
with significant side effects. [12-16]  114 
 115 
Non-pharmacological therapies for refractory chronic cough have shown promising results in 116 
a few studies and no significant adverse effects. [17] Non-pharmacological therapies are 117 
generally delivered by physiotherapists or speech and language therapists and key components 118 
include: education, cough suppression techniques including breathing exercises, vocal hygiene 119 
and hydration and psycho-educational counselling. [15, 17-23] Vertigan et al, [19] conducted 120 
the only  randomised controlled trial of a non-pharmacological intervention for refractory 121 
chronic cough and found  significantly greater improvements in symptoms of cough for speech 122 
pathology management compared to control (general healthy lifestyle advice). The benefits of 123 
speech pathology management on objectively measured cough frequency, cough reflex 124 
sensitivity and health related quality of life (HRQoL) have not been assessed in a controlled 125 
clinical trial, limiting the generalisability of the findings. The minimal clinically important 126 
difference of the cough symptom score used in this study has not been defined. Furthermore, 127 
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the longer term effect of therapy is not known. [17] A recent study by Patel et al [20] 128 
investigated cough-suppression physiotherapy for refractory chronic cough in 23 participants 129 
and found a significant improvement in cough related quality of life but this study also did not 130 
include a control intervention.  131 
 132 
This study therefore aimed to assess the effect of an intervention utilising both physiotherapy 133 
and speech and language therapy techniques (Physiotherapy, Speech and Language Therapy 134 
Intervention, PSALTI) on HRQoL, objective cough frequency, cough reflex sensitivity and 135 
cough severity using a randomised controlled design. 136 
 137 
METHODS 138 
A multi-centre, single blinded randomised controlled trial was conducted across three hospitals 139 
in the UK (King’s College Hospital NHS Foundation Trust, Lancashire Teaching Hospitals 140 
NHS Foundation Trust and Northumbria Healthcare NHS Foundation Trust). Two further sites, 141 
Royal Brompton & Harefield NHS Foundation Trust and Guy’s and St Thomas’ NHS 142 
Foundation Trust) were recruitment only sites and patients were referred to King’s College 143 
Hospital to receive the intervention. The study was undertaken between December 2011 and 144 
April 2014. 145 
 146 
Participants and randomisation 147 
Eligible patients were identified as adults with chronic cough (defined as duration greater than 148 
2 months), with normal chest x-ray, minimal sputum production (less than 10ml sputum a day) 149 
and who had negative investigations and/or failed treatment trials for asthma, gastroesophageal 150 
reflux and, rhinitis as per British Thoracic Society guidelines. [1] Patients were excluded if 151 
they: had an upper respiratory tract infection in past four weeks, were taking angiotensin 152 
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converting inhibitor (ACE-I) medication, were current smokers, or had a known respiratory 153 
disease (such as lung cancer, pneumonia, pulmonary fibrosis, sarcoidosis, pleural effusion, 154 
bronchiectasis). Patients were also excluded if they had vocal cord nodules, malignancy, or 155 
evidence of active aspiration.  156 
 157 
Once participants had given written consent and completed baseline assessments, they were 158 
registered into the randomisation service provided by the King’s Clinical Trials Unit, King’s 159 
College London. This prevented foreknowledge of treatment assignment for the study 160 
researchers. Group allocation was concealed from participants until they had completed the 161 
study and all post-intervention assessments. Patients were block randomised, stratified by age 162 
(above and below 50 years old) and gender.  163 
 164 
Control intervention 165 
Participants attended weekly sessions and received one to one standardised healthy lifestyle 166 
advice  from a health care professional (nurse, physiotherapist or speech and language therapist) 167 
over four weeks. The control intervention was based on that used in the trial reported by 168 
Vertigan et al. [19] The initial session covered general advice on exercise and physical activity, 169 
second session dietary and nutritional advice, third session stress management and fourth 170 
session relaxation. The material covered in each session was based on healthy lifestyle advised 171 
by the United Kingdom Department of Health and National Health Service. [24-26] The 172 
sessions were standardised for all sites by using the same written prompts for therapists and 173 
educational information. Face to face training was provided for all site therapists who delivered 174 
the healthy lifestyle intervention.  The duration of all trial sessions was 45 minutes except the 175 
initial session which was one hour. 176 
 177 
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PSALTI intervention 178 
Participants attended weekly sessions, and received one to one treatment from a health care 179 
professional (physiotherapist or speech and language therapist) over four weeks. Session 180 
durations were the same as for the control group. The intervention was based on previous 181 
speech pathology management and cough-suppression physiotherapy studies for refractory 182 
chronic cough reported by Vertigan et al and Patel et al respectively (Table 1). [19, 20] The 183 
first session focused on educating participants about chronic cough, introduction to laryngeal 184 
hygiene and hydration techniques and cough suppression/distraction. The second and third 185 
sessions covered cough suppression techniques in more detail including breathing exercises 186 
(table 1). Nasal douching or steam inhalations were recommended to patients with nasal 187 
congestion. In the third session psycho-educational counselling techniques were covered with 188 
the aid of an information booklet developed jointly by the lead researcher and clinical 189 
psychologist at the primary research site. The fourth session consisted of reinforcing all aspects 190 
of PSALTI. All components of PSALTI were delivered, however the focus and emphasis on 191 
individual techniques varied for each participant, determined by the treating therapist. Airway 192 
clearance techniques were included in the PSALTI treatment if the participant’s sputum 193 
production was close to the upper limit of sputum exclusion criteria. The standardisation of 194 
treatment between different hospitals was increased by the use of written treatment plans and 195 
educational material.  All therapists delivering the treatment were trained in PSALTI prior to 196 
commencing the study by the main study researcher.  197 
 198 
 199 
 200 
 201 
Table 1: PSALTI components  202 
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 203 
PSALTI 
component 
Technique 
Education Educate patients on the cough reflex, chronic cough and cough reflex 
hypersensitivity. 
Explain the negative effects of repeated coughing 
Educate patients on voluntary control of cough 
Laryngeal 
hygiene and 
hydration 
Increase frequency and volume of water and non-caffeinated drinks 
Reduce caffeine and alcohol intake 
Promote nasal breathing 
Cough control Teach patients to identify their cough triggers 
Teach patients to use cough suppression or distraction techniques at 
the first sign or sensation of the need or urge to cough. These cough 
suppression/distraction techniques include: forced swallow, sipping 
water and sucking sweets. 
Teach patients breathing exercises: breathing pattern re-education 
promoting relaxed abdominal breathing pattern technique; pursed lip 
breathing to use to control cough. 
Psycho-
educational 
counselling 
Motivate patients, reiterate the techniques and the aims of therapy 
Behaviour modification: to try to reduce over-awareness of the need to 
cough 
Stress and anxiety management 
Modified from Chamberlain et al [18] 204 
 205 
Primary Efficacy Endpoint 206 
HRQoL was assessed with the Leicester Cough Questionnaire (LCQ) at week four, the primary 207 
endpoint. [8] The LCQ is a validated 19-item cough-specific health-related quality of life 208 
questionnaire. Overall scores range from three to twenty-one with a higher score indicating a 209 
better HRQoL. The minimal important difference for this outcome is 1.3. [27]   Participants 210 
independently completed questionnaires at baseline, at four weeks (after 4th treatment session) 211 
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and at three month follow up. Questionnaires were then placed in sealed envelopes to avoid 212 
influencing the treating therapist. 213 
 214 
Secondary Efficacy Endpoints 215 
Secondary endpoints were assessed at baseline, 4 weeks and 3 months. Objective cough 216 
frequency was assessed with the Leicester Cough Monitor (LCM) a validated, objective, 217 
automated and ambulatory cough monitoring device. [28] The LCM consists of a MP3 218 
recording device (Phillips 662 MP3 recorder, UK), external microphone and automated cough 219 
detection software. The LCM has been used in previous clinical trials of gabapentin and 220 
erythromycin. [12, 29] Participants wore the device for 24 hours at baseline, at four weeks (after 221 
fourth treatment session) and three month follow up and were instructed to resume their normal 222 
daily activities during this time period. The number of coughs per hour (CFperhour) were 223 
recorded. 224 
 225 
Capsaicin cough challenge was assessed in a subset of the participants (Kings College Hospital 226 
Foundation Trust and Northumbria Healthcare NHS Foundation Trust) to measure participants’ 227 
cough reflex sensitivity at baseline and at four weeks (after fourth treatment session). Doubling 228 
concentrations of capsaicin solution ranging from 0 (saline), 0.49µm to 1000 µm were 229 
administered as per European Respiratory Society guidelines. [30] A dose-response capsaicin 230 
cough testing method was used. [30] The nebuliser output was set to 0.01mL.breath-1. The test 231 
was discontinued when five or more coughs were induced (C5). In addition, the dose that 232 
induced two or more coughs (C2) was recorded.  233 
 234 
Cough severity in the past 2 weeks was assessed by a visual analogue scale (0-100mm) as per 235 
American College of Chest Physicians guidelines. [31] The vocal performance questionnaire 236 
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(VPQ), [32] a 12 item tool was used to assess patients’ perceived impact on their voice, since 237 
a high prevalence of voice disorders in patients with chronic cough has been reported [33]. A 238 
score >12 indicates dysphonia. [32] General health and mood was assessed by Short-Form 36 239 
(SF36) and Hospital Anxiety and Depression scale (HADs). [35, 36] HADs is 14-item 240 
questionnaire, a score for either subscale ≥eight indicates mild symptoms, ≥11 moderate and 241 
≥15 severe. SF-36 generates two summary scores, physical component summary score (PCS) 242 
and mental component summary score (MCS); both range from zero to hundred and a higher 243 
score indicates better self-reported health. [37] 244 
 245 
Ethics and trial registration 246 
All protocols were approved by the London-Chelsea National Research Ethics Service (NRES) 247 
Committee (11-LO-0504). All participants provided written informed consent, and the study 248 
was registered with the UK Clinical Research Network (UKCRN ID 10678) and ISRCTN 249 
(ISRCTN 73039760). 250 
 251 
Role of funding source  252 
The funding bodies had no role in study design, collection, analysis and interpretation of data, 253 
in the writing of the report or in the decision to submit for publication. 254 
 255 
STATISTICAL ANALYSIS AND SAMPLE SIZE 256 
Power calculations for the primary outcome (LCQ score) were performed based on estimates 257 
from a previous study, [38] reporting a mean LCQ score in patients with chronic cough of 14.03 258 
(SD: 3.87). [38] Group sample sizes of 33 in each group achieve 80% power with a significance 259 
level of 5% to detect a LCQ change of 2.7 (seen in our pilot study). Allowing for a 25% drop 260 
out we aimed to recruit 88 patients in total.  261 
Page 13 of 41 
 
 262 
For each of the variables analysed, univariate descriptive statistics were summarised by 263 
randomised group to provide an overview of the data. Summary measures for the baseline 264 
characteristics of each group were presented as mean and standard deviation for continuous 265 
‘approximate’ normally distributed variables, medians and interquartile ranges for non-266 
normally distributed variables, and frequencies and percentages for categorical variables. 267 
Univariate analyses were performed to compare study group using appropriate statistical tests 268 
according to the type and the distribution of the data: independent t-test or Mann-Whitney for 269 
continuous variable. Cough frequency and capsaicin data were log transformed prior to 270 
analysis.  271 
 272 
Primary efficacy analysis, change in LCQ at week 4, was based on analysis of covariance 273 
(ANCOVA) adjusted for the baseline LCQ measurements. The ANCOVA analysis was 274 
repeated to adjust for centre and speciality of treating therapist. The analysis used data from the 275 
intention-to-treat basis (ITT) population, which included all randomised participants who had 276 
received at least one treatment session. In this analysis only observed data were included and 277 
no imputation was used for missing data.  We also performed an analysis on a per-protocol 278 
population (PP) which included patients who completed end of treatment (week 4) cough 279 
assessments and who did not deviate from the protocol (established before unmasking). 280 
Sensitivity analyses were performed for missing data according to different predefined 281 
populations using ANCOVA, with multiple imputations (Online appendix - Table 1). [39] 282 
Similar sensitivity analyses were also performed for objective log-transformed cough 283 
frequency endpoints (Online appendix - Table 2). 284 
 285 
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The secondary efficacy analysis used data from the intention-to-treat population. In these 286 
analyses ANCOVA was used adjusting for baseline variables and only observed data were 287 
included without imputation for missing data. A p-value of less than 0.05 was considered 288 
statistically significant.  All analyses were made using STATA version 12 software (StataCorp 289 
LP, College Station, TX).   290 
 291 
RESULTS  292 
Participants 293 
Seventy-five participants were randomised and had baseline assessments. One additional 294 
patient was randomised to the PSALTI group but did not attend baseline assessments. Four 295 
participants did not receive any treatment (PSALTI group (n=3): myocardial infarction prior to 296 
treatment, unable to travel to hospital and insufficient time for the study;  control group (n=1): 297 
undisclosed illness prior to start of treatment). The intention to treat population for LCQ 298 
primary analysis consisted of 71 participants (Figure 1 and Online Appendix - Table 1). A total 299 
of four participants in the control group and eight participants in the PSALTI group did not 300 
receive or complete all treatments for reasons stated in Figure 1. Forty-nine participants 301 
completed three month follow up. The consort study flow is described in Figure 1. The baseline 302 
characteristics of the randomised participants are described in Table 2. The groups were  well-303 
matched with the exception of SF36 Physical Component Summary Scores (higher in the 304 
control group).     305 
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Table 2. Baseline demographic and clinical characteristics of randomised study participants. 306 
 307 
Characteristic 
 
Control (n=41) PSALTI (n=34) p 
value 
Age (years)  56 (48 to 67)  61 (53 to 67) 0.239 
Female, n (%)  26 (63)  25 (71) 0.459 
Cough duration (months)  48 (24 to 126)  60 (30 to 126) 0.279 
FEV1 (L, observed), mean(SD)  2.7 (0.9)  2.6 (0.7) 0.517 
FEV1/FVC (%), mean(SD)  76 (8.2)  76  (5.0) 0.686 
LCQ, mean(SD)  11.9 (3.5)  10.4 (3.6) 0.073 
Cough Severity VAS  65 (40 to 83)  63 (49 to 75) 0.652 
SF-36 PCS,   47.1 (41.7 to 53.6)  41.1 (35.6 to 49.1) 0.033* 
SF-36 MCS  47.7 (38.3 to 54.9)  49.9 (40.5 to 57.0) 0.763 
HADs –Anxiety  7 (3 to 10)  7 (4 to 10) 0.785 
HADs – Depression  4 (1 to 8)  5 (2 to 6) 0.620 
VPQ  17 (11 to 22)  21 (13 to 27) 0.158 
CFperhour #  17.0 (0.4)  17.0 (0.4) 0.983 
C2 (µm) #  4.01(0.69)  4.74 0.62) 0.677 
C5 (µm) #  9.33 (0.56)  8.25 (0.51) 0.708 
Data presented as median (IQR) unless otherwise stated.  308 
 309 
*p<0.05, # Geometric mean (log SD) 310 
 311 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LCQ, Leicester cough questionnaire; 312 
VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, Physical component score; MCS, Mental 313 
component score; HADs, hospital anxiety and depression scale; VPQ, vocal performance questionnaire; CFperhour, 314 
cough frequency per hour over a 24 hour period; C2, capsaicin cough challenge –  concentration that resulted in 315 
two or more coughs;  C5, capsaicin cough challenge –  concentration that resulted in five or more coughs. 316 
 317 
HRQoL - Primary Efficacy Endpoint 318 
 319 
There was an improvement in the mean total LCQ score at four weeks with PSALTI; baseline 320 
10.4 vs. four-weeks 14.4, mean difference 3.4, p<0.001. This improvement was larger than that 321 
in the control group; baseline mean 11.9 vs. 13.4 at four-weeks, mean difference 1.66, p<0.001 322 
(Online Appendix – Table 3). Total LCQ score at four weeks improved by a mean 1.53 (95% 323 
CI 0.21 to 2.85) units more in the PSALTI group than in control (p=0.024), table 3.  When 324 
adjusted for centre and speciality of therapist, the LCQ score at four weeks improved by a mean 325 
Page 16 of 41 
 
of 1.53 (95% CI 0.20 to 2.86), p=0.024. The improvement in LCQ with PSALTI  was consistent 326 
in the per-protocol and sensitivity analyses (Online Appendix - Table 1). The LCQ 327 
improvement was sustained from week 4 to  3 months for both groups but there was no 328 
significant difference between groups at 3 months (table 3). The LCQ scores and within group 329 
differences are presented in online supplement Table 3 and Table 4 respectively.  Primary 330 
outcome LCQ data (baseline or week 4) was missing in 6.7% of participants. There were no 331 
adverse or serious adverse events reported for both interventions. 332 
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Table 3. Primary and Secondary efficacy endpoint analysis: Change between PSALTI and control groups at baseline to four weeks and four weeks to three month 
follow up 
 
 Between group difference 
Baseline to four weeks 
Between group difference 
Four weeks to three month follow up 
Mean Difference (95% CI) p value Mean Difference (95% CI) p value 
LCQ Total     1.53 (0.21 to 2.85)      0.024         0.01 (-1.62 to 1.64) 0.994 
CFperhour (fold change)     0.59 (0.36  to 0.94)      0.030         1.01 (0.55 to 1.86)         0.966 
VAS severity    -9.72 (-20.80 to 1.36)      0.084         1.6 (-15.48 to 18.74) 0.848 
SF36 PCS     0.56 (-2.52 to 3.64)      0.717         0.48 (-3.27 to 3.37) 0.977 
SF36 MCS     0.81 (-3.10 to 4.72)      0.680         0.72 (-3.06 to 4.51) 0.703 
VPQ     3.90 (-0.33 to 8.12)      0.070        -0.20 (-3.43 to 3.03) 0.901 
HADS – Anxiety    -0.42 (-1.96 to 1.13)      0.590         0.88 (-0.57 to 2.34) 0.225 
HADS – Depression    -0.44 (-1.69 to 0.81)      0.486        -0.18 (-1.36 to 0.99) 0.753 
C2 (fold change)     1.11 (0.76 to 1.61)      0.575 NA NA 
C5 (fold change)     1.11 (0.80 to 1.54)      0.512 NA NA 
 
Between group differences were calculated using ANCOVA adjusted for baseline values.  
Positive change in LCQ, SF36 PCS, SF36 MCS, and C5 indicates improvement in symptoms. Negative change in VAS, VPQ, HADS indicates improvement in 
symptom.  
LCQ, Leicester cough questionnaire; CFperhour, cough frequency per hour over a 24 hour period; VAS, visual analogue scale; SF-36, short-form 36 questionnaire; 
PCS, Physical component score; MCS, Mental component score; VPQ, vocal performance questionnaire HADS, hospital anxiety and depression scale; C2, 
concentration of capsaicin that caused ≥2 coughs, C5,concentration of capsaicin that caused ≥5 coughs, NA – not assessed at this time point. 
                   *p<0.05 
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Objective Cough Frequency 337 
There was a greater reduction in cough frequency after four weeks of treatment in the PSALTI 338 
group; geometric mean (SD) 17.0 (2.4) to 9.0 (3.3) coughs per hour (p=0.002) versus 17.0 (2.3) 339 
to 16.0 (2.2) coughs per hour after control (p=0.205), table 4. The control-adjusted improvement 340 
in cough frequency per hour in PSALTI was 41% (95% CI [36-95%], p=0.030, ANCOVA) at 341 
4 weeks in the primary ITT analysis, (table 3). This improvement was also sustained at three 342 
months (Figure 2).  The reduction in cough frequency with PSALTI was consistent in per-343 
protocol and sensitivity analyses (Online Appendix - Table 2).  344 
 345 
Other questionnaire data 346 
There were no significant between group differences for change (week four minus baseline) in 347 
VPQ, depression, anxiety or SF36 (Table 3).  There was a greater reduction in VAS cough 348 
severity in the PSALTI group compared to control (p=0.084, Table 3). There was a reduction 349 
in cough severity VAS within groups between week 4 to baseline; control p=0.007, PSALTI 350 
p<0.001 (Table 4).  351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
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Table 4: Primary and Second Efficacy Endpoints : within group change  
 Change from baseline to  four weeks Change from four weeks to three month follow up 
PSALTI 
Mean Difference      
(95% CI) 
P Control 
Mean Difference 
(95% CI) 
P PSALTI 
Mean Difference 
(95% CI) 
P Control 
Mean Difference (95% 
CI) 
P 
LCQ Total mean 3.40                                
(2.26 to 4.55) 
0.001* 1.66                      
(0.78 to 2.54) 
<0.001* -0.17                          
(-1.49 to 1.15) 
0.794 0.27                              
(-0.82 to 1.35) 
0.616 
CFperhour (fold change) 0.55                             
(0.33 to 0.75) 
0.002 0.82                        
(0.60 to 1.22) 
0.2053 1.26                         
(0.84 to 1.90) 
0.236 0.91                               
(0.59 to 1.39) 
0.655 
VAS severity -21.18                              
(-29.83 to -12.53) 
<
0.001* 
-11.84                        
(-20.11 to -3.57) 
0.007* 9.74                           
(-3.60 to 23.08) 
0.143 0.79                              
(-10.73 to 12.31) 
0.888 
C2 (fold change) 1.28                            
(0.96 to 1.71) 
0.089 1.06                       
(0.81 to 1.36) 
0.666 NA NA NA NA 
C5 (fold change) 1.24                                
(1.02 to 1.50) 
0.035* 1.08                              
(0.87 to 1.36) 
0.469 NA NA NA NA 
SF36 PCS 1.62                                   
(-0.96 to 4.21) 
0.208 0.50                               
(-1.30 to 2.31) 
0.574 0.54                           
(-1.82 to 2.89) 
0.639 0.76                              
(-1.66 to 3.18) 
0.522 
SF36 MCS 0.53                                   
(-2.69 to 3.75) 
0.736 -0.26                            
(-2.92 to 2.40) 
0.843 1.09                             
(-1.91 to 4.09) 
0.456 0.49                               
(-2.35 to 3.32) 
0.727 
VPQ 4.04                                   
(0.12 to 7.97) 
0.044* 0.73                              
(-1.94 to 3.39) 
0.582 -1.63                           
(-4.17 to 0.91) 
0.193 -0.57                             
(-3.29 to 2.15) 
0.666 
HADS – Anxiety -1.27                                
(-2.51 to -0.032) 
0.045* -0.90                            
(-1.96 to 0.17) 
0.095 -0.11                               
(-1.16 to 0.94) 
0.826 0.95                                 
(-0.22 to 2.11) 
0.104 
HADS – Depression -0.68                                 
(-1.57 to 0.21) 
0.126 -0.21                             
(-1.11 to 0.69) 
0.641 0.06                           
(-1.42 to 1.53) 
0.937 0.05                              
(-0.66 to 0.76) 
0.878 
 
Positive change in LCQ, SF36 PCS, SF36 MCS indicates improvement in symptoms. Negative change in VAS, VPQ and HADS indicates improvement in symptoms. LCQ, 
Leicester cough questionnaire; CFperhour, cough frequency per hour over a 24 hour period; C2, capsaicin cough challenge concentration that resulted in two or more coughs - 
C5, capsaicin cough challenge –  concentration that resulted in five or more coughs; VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, Physical component 
score; SF-36 MCS, Mental component score; VPQ, vocal performance questionnaire HADS, hospital anxiety and depression scale. NA – not assesses at this timepoint 
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Cough reflex sensitivity 361 
Sixty participants (80% of ITT group) underwent capsaicin challenge. No significant 362 
differences between groups were observed for C2 (p=0.575) or C5 (p=0.512) (Table 3).  There 363 
was a within group reduction in C5 with PSALTI (p=0.035) but not with control (p=0.469), 364 
table 4. 365 
  366 
DISCUSSION 367 
 368 
This study evaluated the efficacy of a physiotherapy and speech and language therapy 369 
intervention for patients with refractory chronic cough in a randomised controlled trial.   There 370 
was a clinically and statistically significant improvement in health-related quality of life with 371 
PSALTI compared to control intervention.   This was supported by a significant reduction in 372 
cough frequency measured objectively.  The improvement in health-related quality of life was 373 
sustained at a three-month follow-up visit.   There was no significant change in cough reflex 374 
sensitivity between groups. 375 
 376 
Our findings represent an advance from those reported in an earlier study by Vertigan et al. 377 
[19]   Our study is the first multi-centre trial reported in chronic cough and has the potential to 378 
provide the evidence base for access to therapy. Vertigan et al reported a statistically significant 379 
reduction in cough symptoms scores but did not include HRQoL or objective assessment with 380 
cough frequency monitors. [19]   In contrast we assessed HRQoL, objective cough frequency, 381 
cough severity VAS and cough reflex sensitivity.  We were also able to demonstrate both a 382 
clinically and statistically significant improvement in our primary endpoint because the 383 
minimally important difference (MID) of the LCQ has been defined. [27] We have shown that 384 
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the benefits of PSALTI are sustained after discontinuation of therapy, in contrast to Vertigan 385 
et al who did not report follow up data for their participants. [19] One of the strengths of our 386 
study was the involvement of multiple centres, the use of standardised treatment protocols and 387 
the inclusion of both physiotherapists and speech and language therapists delivering the 388 
treatment.  389 
 390 
HRQoL, as assessed with the Leicester Cough Questionnaire (LCQ) was selected as the 391 
primary outcome measure because it is perhaps the most important outcome measure from the 392 
patient’s perspective. [7, 8, 40] The HRQoL of our patients was severely impaired, affecting 393 
physical, psychological and social domains, comparable to that reported in previous studies of 394 
refractory chronic cough. [29, 41] The improvement of HRQoL with PSALTI was large, LCQ 395 
3.4 units.   This improvement was greater than the MID of the LCQ, 1.3 units, [27] and that 396 
reported for Gabapentin therapy in patients with refractory chronic cough (LCQ improvement 397 
2.5 units). [12] The improvement with PSALTI was smaller when adjusted for the change in 398 
the control group (LCQ score control group 1.66 units). HRQoL also improved with control 399 
intervention, but to a lesser extent than PSALTI.  The aim of the control intervention was to 400 
provide patients with an equivalent quantity of clinical attention to the PSALTI intervention.   401 
This is additional to what most patients with  refractory chronic cough would receive as usual 402 
care since physiotherapy and speech and language therapy services are not widely available for 403 
refractory chronic cough.  It is possible that the control intervention had an anti-tussive effect 404 
and that the difference between PSALTI and control group may have been larger if compared 405 
to usual care (no active treatment). The control intervention was intended to be non-specific 406 
but it is possible that some of its components such as stress/anxiety and lifestyle management 407 
may have had a positive benefit, particularly on the central sensitisation pathways that regulate 408 
cough. 409 
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 410 
The improvement in cough frequency assessed objectively with 24-hour cough monitoring 411 
supports the improvement in HRQoL with PSALTI occurred because of an actual reduction in 412 
coughing.   Cough frequency outcome measures are increasingly being used as end-points in 413 
clinical trials to validate the efficacy of anti-tussive therapy. [42, 43] The Leicester Cough 414 
Monitor (LCM) has been reported to be a valid method of counting coughs objectively. [28, 415 
44] An advantage of cough monitors over subjective measures is that they are not susceptible 416 
to the patient’s or clinician’s perception of cough severity.   PSALTI intervention was 417 
associated with an additional 41% reduction in cough frequency, which can be considered a 418 
large change and is comparable to that observed with pharmacotherapy such as the P2X3 419 
inhibitor AF-219. [13] The minimal clinically important difference for cough monitor 420 
frequency in chronic cough has not been studied.  The reduction of cough frequency was 421 
comparable to the minimal important difference reported for acute cough. [42] We also 422 
assessed cough severity subjectively with VAS.   There was a reduction in cough severity with 423 
PSALTI compared to control intervention, and the difference approached statistical 424 
significance.  The reason for the discrepancy in effect size between HRQoL and VAS findings 425 
is not clear.   A larger study would be needed to confirm whether PSALTI impacts cough 426 
assessed with VAS. Despite their widespread use, VAS have been poorly validated in 427 
comparison to HRQoL questionnaires and cough monitoring tools, as acknowledged by the 428 
American College of Chest Physicians’ Cough Guidelines. [31] There were no between group 429 
differences in reported voice related problems. We chose the VPQ, a patient reported 430 
questionnaire, to assess voice since it has been reported to have excellent internal consistency, 431 
repeatability and responsiveness. [34] There are alternative questionnaires available to assess 432 
voice such as the voice handicap index and voice symptom scale [45, 46].  A comparison of 433 
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these scales by Webb et al concluded all were valid and reliable questionnaires for assessing 434 
patient’s perceived voice dysfunction [34]. 435 
There were no adverse events associated with PSALTI, specifically no episodes of pulmonary 436 
infections.  Patients with significant sputum production were excluded because of the potential 437 
risk of pulmonary infections associated with cough suppression.  Longer-term data with 438 
PSALTI is required to fully assess its safety.   The mechanism by which PSALTI reduces cough 439 
is not clear, nor which component of PSALTI is most effective.   PSALTI was not associated 440 
with a reduction in cough reflex sensitivity assessed with capsaicin when compared to the 441 
change in control group. There was however a significant within group reduction in C5 in the 442 
PSALTI group which is consistent with studies by Ryan et al and Vertigan et al, who reported a 443 
reduction in cough reflex sensitivity with speech pathology management. [21, 15] The Ryan et 444 
al and Vertigan et al studies however did not have a control group (no speech pathology 445 
management) for comparison. It is possible that we did not find a between group difference in 446 
cough reflex sensivity due to the small sample size of participants that underwent capsaicin 447 
cough challenge testing; further studies are needed to investigate this.  448 
  449 
We investigated PSALTI in patients with refractory chronic cough.  Our patients had a 450 
troublesome chronic cough despite numerous investigations and trials of therapy. A refractory 451 
chronic cough may also be referred to as idiopathic, difficult to treat, unexplained, sensory 452 
neuropathic and vagal neuropathy cough although some differences exist between groups. [47] 453 
PSALTI type treatments have only been studied in patients with refractory chronic cough once 454 
they have undergone extensive investigations and/or trials of therapy. The role of PSALTI type 455 
treatments earlier in the management of such patients has not been explored and needs to be 456 
studied. The efficacy of PSALTI is also unknown in other difficult to treat coughs, such as that 457 
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associated with lung cancer, idiopathic pulmonary fibrosis and sarcoidosis and this should be 458 
investigated. Further studies are needed to explore the optimum frequency and duration of 459 
PSALTI and other non-pharmacological treatments. 460 
 461 
There were some limitations to our study.  The study was single-blinded.  It was not possible 462 
to blind the treating therapist to the intervention the patient received.   The possibility that 463 
unconscious bias could have been conveyed to participants during the course of intervention 464 
cannot therefore be discounted. Double blinding is not possible in studies of behavioural 465 
intervention. The potential bias was minimised by asking patients to complete their primary 466 
outcome measures independently from the treating therapist and participants remained blinded 467 
until after completion of the final post-intervention outcome measures. Capsaicin cough reflex 468 
tests in some patients were performed by the treating therapist but it is unlikely this influenced 469 
the outcome since our findings  suggest no change with intervention when adjusted for control. 470 
Some components of PSALTI were tailored to the individual, according to clinical need. This 471 
may be considered both a limitation and a strength since it reduces the uniformity of 472 
intervention delivered but reflects real life clinical practice addressing the needs of an 473 
individual.  Our study did not meet the intended sample size. This may have affected the power 474 
of our analyses and undermined the robustness of the results. Despite this, there was a clinically 475 
and statistically significant improvement in the primary outcome measure with PSALTI. 476 
Thirty-six (22%) of subjects screened were uncontactable or declined to participate. The 477 
clinical characteristics of participants recruited were however consistent with previously 478 
reported studies of refractory chronic cough [29]. A significant number of patients were lost to 479 
follow up for the 3 month visit where secondary endpoints were assessed. This was largely 480 
from the control group. There was no significant difference in LCQ between groups at 3 481 
months; this could be a consequence of a smaller sample size or a reduction in the long term 482 
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benefit of PSALTI following cessation of therapy. The long term benefits of PSALTI needs to 483 
be confirmed in larger studies. It is possible that some of the benefit of PSALTI may have been 484 
a consequence of intense supervision. The control intervention was however identical in 485 
frequency and duration of visits.  486 
 487 
In conclusion, PSALTI is an effective therapy for patients with refractory chronic cough.   It is 488 
associated with a significant improvement in health-related quality of life, and cough frequency 489 
compared to control.   The optimal components of PSALTI and number of sessions of therapy 490 
need to be determined in future studies.   The effectiveness of PSALTI used earlier in the 491 
treatment of chronic cough and other patient groups with difficult-to-treat cough, should be 492 
evaluated.  There is also a need for improved access to physiotherapy and speech and language 493 
therapy services for patients with refractory chronic cough. 494 
 495 
 496 
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FIGURE LEGENDS 534 
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Figure 1. Trial CONSORT flow diagram 536 
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Figure 2. Change in objective cough frequency in PSALTI and control groups  538 
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Figure. 1. Trial CONSORT flow diagram  714 
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*One additional participant was randomised and withdrew before baseline assessments.  745 
  746 
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31 
 Received allocated intervention and 
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Figure 2: Change in objective cough frequency in PSALTI and control groups  747 
 748 
 749 
Data presented as Geometric Mean (log 95%CI) coughs per hour. PSALTI: physiotherapy 750 
speech and language therapy intervention.  751 
 752 
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Online Appendix  754 
Supplementary Methods: Sensitivity Analysis 755 
A total of 75 patients were randomised and underwent baseline assessment. One additional 756 
patient was randomised but then declined participation in the trial before baseline measures 757 
could be assessed. All patients were reviewed on a case-by-case basis prior to data unblinding 758 
and analysis, to identify patients for sensitivity analyses.  759 
The following populations were defined for the primary efficacy analysis: 760 
1) All randomised patients who had baseline assessment.   761 
2) Intention to treat (ITT): all patients who received at least one treatment session. 762 
3) All patients who received at least one treatment session and, in addition, had not been 763 
withdrawn from study treatment prior to week 4. 764 
4) Per protocol: all patients who had both baseline and week 4 measurements and did not 765 
deviate from protocol.   766 
Sensitivity analysis was done on predefined populations using analysis of covariance adjusted 767 
for baseline measurements ANCOVA, with multiple imputation method for missing data. 768 
Multiple imputation method used was based on multivariate normal regression using an 769 
iterative Markov chain Monte Carlo (MCMC) method to impute missing values. The 770 
imputation process was repeated to create 10 multiple imputed datasets. Missing week 4 771 
Leicester Cough Questionnaire were imputed, as long as baseline data was available. Hence no 772 
values were imputed where data was missing for both baseline and week 4 in a period. For 773 
cough frequency, data were imputed when week 4 values were missing, in a secondary analysis 774 
using ANCOVA, with multiple imputation method. 775 
Online supplement Table 1 and 2 summarise sensitivity analyses results of LCQ and ‘log’ 776 
cough frequency per hour. 777 
778 
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Online Supplement Table 1: Sensitivity analyses for LCQ. 779 
 780 
Population Imputation method N Estimate [95% CI] p-value 
      
Randomised patients* ANCOVA, with Multiple 
imputation 
75 1.6 0.14 to 2.95 0.032 
      
All patients who 
received at least one 
study treatment (ITT) 
ANCOVA, with Multiple 
imputation 
71 1.5 0.20 to 2.76 0.024 
      
All patients who 
received at least one 
study treatment and 
had not deviated the 
protocol 
ANCOVA, with Multiple 
imputation 
67 1.4 0.08 to 2.78 0.039 
      
Per Protocol ANCOVA, no imputation 63 1.5 0.21 to 2.85 0.024 
 781 
ANCOVA: analysis of covariance analysis, N: sample size; CI: confidence intervals, LCQ: Leicester Cough 782 
Questionnaire (cough specific quality of life). ITT: intention to treat 783 
 784 
*All randomised patients with baseline assessment (excludes 1 patient randomised who then declined 785 
participation and no baseline assessment). 786 
 787 
  788 
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 789 
Online supplement Table 2: Sensitivity analyses results of mean fold difference in cough 790 
frequency per hour.  791 
  792 
Population Imputation method N Estimate [95% CI] p-value 
      
Randomised patients* ANCOVA, with Multiple 
imputation 
69 0.58 0.34 to 0.98 0.043 
      
All patients who 
received at least one 
study treatment (ITT) 
ANCOVA, with Multiple 
imputation 
66 0.59 0.35 to 1.00 0.049 
      
All patients who 
received at least one 
study treatment and 
had not deviated the 
protocol 
ANCOVA, with Multiple 
imputation 
63 0.57 0.36 to 0.90 0.019 
      
Per Protocol ANCOVA, no imputation 53 0.59 0.36 to 0.95 0.030 
 793 
 794 
ANCOVA: analysis of covariance analysis, N: sample size; CI: confidence intervals. ITT: intention to treat 795 
 796 
*All randomised patients with baseline assessment (excludes one patient who was randomised then decline 797 
participation). 798 
 799 
 800 
  801 
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Online supplement Table 3: Leicester Cough Questionnaire HRQoL scores. 802 
 803 
 
PSALTI Group Control Group 
Baseline 10.4 (3.6) 11.9 (3.5) 
Four weeks 14.4 (3.3) 13.4 (3.7) 
Three Months 14.8 (3.9) 13.6 (3.4) 
 804 
Data presented as Mean (standard deviation). HRQoL: health related quality of life. PSALTI: physiotherapy and 805 
speech and language therapy. 806 
 807 
 808 
 809 
